Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2,5-Dideoxy-2,5-imino-D-glucitol (DGDP or DDI) is a synthetic iminosugar and carbohydrate analog in which the ring oxygen of glucitol is replaced by a nitrogen atom. It is structurally derived from glucitol (sorbitol) and belongs to the class of pyrrolidines. DGDP acts as a potent inhibitor of glycohydrolases and glycosidases—enzymes responsible for breaking down carbohydrates—by binding to their active sites. Its primary target includes xylose isomerase found in certain bacteria. This inhibition can disrupt normal carbohydrate metabolism and has been explored for potential therapeutic applications such as pharmacological chaperoning in lysosomal storage disorders like Gaucher disease[3][5]. The compound was first isolated from Stemona tuberosa but is now synthetically produced[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,5-dideoxy-2,5-imino-d-glucitol.